MX2007005835A - Uso de ribosa-cisteina para tratar hipoxia mejorando el suministro de glutationa y los niveles de atp en las celulas. - Google Patents

Uso de ribosa-cisteina para tratar hipoxia mejorando el suministro de glutationa y los niveles de atp en las celulas.

Info

Publication number
MX2007005835A
MX2007005835A MX2007005835A MX2007005835A MX2007005835A MX 2007005835 A MX2007005835 A MX 2007005835A MX 2007005835 A MX2007005835 A MX 2007005835A MX 2007005835 A MX2007005835 A MX 2007005835A MX 2007005835 A MX2007005835 A MX 2007005835A
Authority
MX
Mexico
Prior art keywords
further characterized
ribcys
hypoxia
mammal
tissue
Prior art date
Application number
MX2007005835A
Other languages
English (en)
Spanish (es)
Inventor
Herbert T Nagasawa
Original Assignee
Bioceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioceuticals Inc filed Critical Bioceuticals Inc
Publication of MX2007005835A publication Critical patent/MX2007005835A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MX2007005835A 2004-11-17 2005-11-16 Uso de ribosa-cisteina para tratar hipoxia mejorando el suministro de glutationa y los niveles de atp en las celulas. MX2007005835A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/990,933 US20060105972A1 (en) 2004-11-17 2004-11-17 Method to enhance delivery of glutathione and ATP levels in cells
PCT/US2005/041458 WO2006055597A1 (en) 2004-11-17 2005-11-16 Use of ribose-cysteine to treat hypoxia by enhancing delivery of glutathione and atp levels in cells

Publications (1)

Publication Number Publication Date
MX2007005835A true MX2007005835A (es) 2007-10-08

Family

ID=35759146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005835A MX2007005835A (es) 2004-11-17 2005-11-16 Uso de ribosa-cisteina para tratar hipoxia mejorando el suministro de glutationa y los niveles de atp en las celulas.

Country Status (14)

Country Link
US (4) US20060105972A1 (enExample)
EP (1) EP1824481B1 (enExample)
JP (1) JP2008520681A (enExample)
KR (1) KR20070095900A (enExample)
CN (1) CN101060840A (enExample)
AU (1) AU2005307885B2 (enExample)
BR (1) BRPI0516814A (enExample)
CA (1) CA2587616C (enExample)
DK (1) DK1824481T3 (enExample)
EA (1) EA014076B1 (enExample)
ES (1) ES2390228T3 (enExample)
MX (1) MX2007005835A (enExample)
PL (1) PL1824481T3 (enExample)
WO (1) WO2006055597A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105972A1 (en) 2004-11-17 2006-05-18 Nagasawa Herbert T Method to enhance delivery of glutathione and ATP levels in cells
JP4982755B2 (ja) * 2006-06-27 2012-07-25 国立大学法人 長崎大学 高速液体クロマトグラフィーによる糖及び類縁アルデヒド化合物の絶対配置決定法
US8685951B2 (en) 2007-03-27 2014-04-01 The Board Of Trustees Of The University Of Arkansas Compositions and methods for cytoprotection
US20100055206A1 (en) * 2008-04-02 2010-03-04 St Cyr John A Use of ribose in first response to acute myocardial infarction
TW201202209A (en) * 2010-01-28 2012-01-16 Max International Llc Methods of preparing thiazolidines
TW201201712A (en) * 2010-01-28 2012-01-16 Max International Llc Compositions comprising sugar-cysteine products
US20110287109A1 (en) * 2010-05-24 2011-11-24 Max International, Llc Compositions And Beverages Comprising Nutrients, Vitamins, Sugars, Cysteine, And/Or Sugar-Cysteine Products
CA2843388A1 (en) * 2011-07-27 2013-01-31 Max International, Llc Compositions comprising sugar-cysteine products
MY190600A (en) * 2015-05-22 2022-04-27 A2 Milk Co Ltd Beta-casein a2 and antioxidant capacity
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (it) 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
US4647571A (en) 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4605644A (en) * 1985-02-07 1986-08-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia employing ribose and adenine
US4719201A (en) * 1985-02-07 1988-01-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia
US4736060A (en) 1985-08-06 1988-04-05 Nippon Rikagakuyakuhin Co., Ltd. Method for optical resolution of DL-cysteine and (R,S)-1-(1-naphthyl) ethylamine
JPS63152325A (ja) 1986-08-20 1988-06-24 Yamanouchi Pharmaceut Co Ltd 脳虚血症予防治療剤
US4868114A (en) * 1987-08-05 1989-09-19 Regents Of The University Of Minnesota Method for elevating glutathione levels
US5095027A (en) * 1991-02-28 1992-03-10 Clintec Nutrition Co. Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid
JP2873089B2 (ja) * 1991-04-15 1999-03-24 帝人株式会社 虚血・再灌流組織障害及び不整脈並びに活性酸素・フリーラジカルによる肺障害の予防又は治療剤
US5631234A (en) * 1991-04-15 1997-05-20 Teijin Limited Method for treating ischemia-reperfusion tissue injury
US5292538A (en) 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
JPH10139665A (ja) * 1996-09-12 1998-05-26 Sankyo Co Ltd トログリタゾンを含有するグルタチオン還元酵素活性増強剤
CA2280093A1 (en) 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
US6730336B2 (en) 1998-01-30 2004-05-04 The Procter & Gamble Co. Fortified beverages with improved texture and flavor impact at lower dosage of solids
US6218366B1 (en) * 1998-06-19 2001-04-17 Bioenergy, Inc. Method for raising the hypoxic threshold
US7153503B1 (en) 1998-12-19 2006-12-26 Janeel Henderson Comprehensive dietary supplement
US6534480B2 (en) * 1999-06-17 2003-03-18 Bioenergy Inc. Compositions for increasing energy in vivo
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US6881425B2 (en) 2001-08-31 2005-04-19 Council Of Scientific And Industrial Research Custom made herbal health promotive formulation for females/expectant mothers
US6572899B1 (en) 2002-07-03 2003-06-03 Vitacost.Com, Inc. Memory loss treatment formulation
US7455857B2 (en) 2003-04-08 2008-11-25 Janeel Henderson Energy generating composition
GB0319463D0 (en) 2003-08-20 2003-09-17 Givaudan Sa Compounds
US20050100537A1 (en) 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
US20060105972A1 (en) 2004-11-17 2006-05-18 Nagasawa Herbert T Method to enhance delivery of glutathione and ATP levels in cells
US8962058B2 (en) 2005-11-23 2015-02-24 The Coca-Cola Company High-potency sweetener composition with antioxidant and compositions sweetened therewith
NZ594596A (en) 2006-02-10 2011-10-28 Mannatech Inc All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
US8685951B2 (en) 2007-03-27 2014-04-01 The Board Of Trustees Of The University Of Arkansas Compositions and methods for cytoprotection
US20100074969A1 (en) 2008-09-19 2010-03-25 Unicity International, Inc. Method of controlling blood sugar levels, insulin levels, cholesterol levels, body fat levels, and body weight by administering a nutrient fiber matrix
TW201201712A (en) 2010-01-28 2012-01-16 Max International Llc Compositions comprising sugar-cysteine products
US20110287109A1 (en) 2010-05-24 2011-11-24 Max International, Llc Compositions And Beverages Comprising Nutrients, Vitamins, Sugars, Cysteine, And/Or Sugar-Cysteine Products

Also Published As

Publication number Publication date
KR20070095900A (ko) 2007-10-01
EA014076B1 (ru) 2010-08-30
AU2005307885A2 (en) 2006-05-26
JP2008520681A (ja) 2008-06-19
ES2390228T3 (es) 2012-11-07
US20060105972A1 (en) 2006-05-18
EA200701017A1 (ru) 2007-10-26
CA2587616C (en) 2015-03-17
US8501700B2 (en) 2013-08-06
AU2005307885A1 (en) 2006-05-26
CN101060840A (zh) 2007-10-24
PL1824481T3 (pl) 2012-11-30
US20160082029A1 (en) 2016-03-24
EP1824481A1 (en) 2007-08-29
US20090042822A1 (en) 2009-02-12
US9144570B2 (en) 2015-09-29
CA2587616A1 (en) 2006-05-26
US20130317072A1 (en) 2013-11-28
DK1824481T3 (da) 2012-09-24
EP1824481B1 (en) 2012-08-29
AU2005307885B2 (en) 2010-12-23
WO2006055597A1 (en) 2006-05-26
BRPI0516814A (pt) 2008-09-23

Similar Documents

Publication Publication Date Title
US9144570B2 (en) Method to enhance delivery of glutathione and ATP levels in cells
FI97891C (fi) Menetelmä 2'-deoksiguanosiinin asyylijohdannaisten valmistamiseksi
US20030232793A1 (en) Use of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disorders
CN112654264A (zh) 使用至少一种甘氨酸或其衍生物、至少一种n-乙酰半胱氨酸或其衍生物和至少一种烟酰胺核糖核苷或nad+前体的组合物和方法
CA2091766C (en) Enhancement of glutathione levels with glutamine
Velvizhi et al. Effects of alpha-ketoglutarate on lipid peroxidation and antioxidant status during chronic ethanol administration in Wistar rats
HK1246682A1 (en) Prophylactic/therapeutic agent for virus infections which comprises ala compound
JPH02503570A (ja) グルタチオンを枯渇する方法
US6943185B2 (en) Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
US11253495B2 (en) Pharmaceutical composition for treating excessive lactate production and acidemia
CN104415023A (zh) 预防或/和治疗胰岛素抵抗及相关病症的组合物
RU2096034C1 (ru) Фармацевтическая композиция, индуцирующая биосинтез глутатиона, активность глутатионтрансферазы и оказывающая антитоксическое, радиопротекторное и антигипоксическое действие, и способы лечения, профилактики и защиты с ее использованием
Sarciron et al. Effects of multiple doses of isoprinosine on Echinococcus multilocularis metacestodes
ES2271265T3 (es) Utilizacion de mangafodipir en el tratamiento de insuficiencia hepatocelular.
HK1114501A (en) Use of ribose-cysteine to treat hypoxia by enhancing delivery of glutathione and atp levels in cells
JP2015518000A (ja) 癌の化学療法剤の投与に関連した副作用の処置のための組成物及び方法
CN107698639A (zh) 一类吉西他滨磷酸酯的n‑甲酸酯乏氧活化前药及其应用
RU2169568C2 (ru) Средство для коррекции энергетического обмена
US20240199601A1 (en) Quinone compound and pharmaceutical use thereof
Jin et al. Recent Advances in the Role of Hydrogen Sulfide in Ischemia-Reperfusion Injury
JPH07149655A (ja) Ｎｏ合成酵素活性化剤
Grishina et al. Accelerated utilization of lactate under the effect of hypoxen after intensive exercise
Lapis et al. Effectiveness of tiazofurin (NSC 286193) in treating disseminated tumor cells and micrometastases in mice
Thölen et al. Effect of coenzyme-A, NAD, alpha lipoic-acid and cocarboxylase on survival of rats with galactosamine-induced severe hepatitis
Plante Excretion of Uric Acid in Man and the Dog

Legal Events

Date Code Title Description
GB Transfer or rights
HC Change of company name or juridical status